Preliminary Evaluation of the Final 11-analyte Classifier.

#The final model was used to score all round one data, excluding those used in model development, and all additional samples unique to round two, which were not used in model development.
*the performance for the stage I samples is an estimate based on the 100-fold bootstrap results.
‡these benign samples are from Correlogic's prospective collection, collected under an IDE to support the development of a clinical test for ovarian cancer. The study population is women scheduled for surgery presenting with symptoms of ovarian cancer. As such, disease status is pathology confirmed following surgery.
¶stage I values are not included in these calculations. 95% CI, 95% confidence interval for the result.